The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
about
Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumorHow drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionDiagnostic and therapeutic biomarkers in pancreaticobiliary malignancyThe Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic CancerPerioperative Therapy for Surgically Resectable Pancreatic AdenocarcinomahENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic reviewNeoadjuvant therapy for pancreas cancer: past lessons and future therapiesSystemic therapies for pancreatic cancer--the role of pharmacogeneticsStructural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transportersPersonalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerUpdate on the management of pancreatic cancer: surgery is not enoughDNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cellsHuman concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake.The Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem CellsImmunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.Equilibrative nucleoside transporters-A review.Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma.Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression.Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levelsConcurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapyHuman equilibrative nucleoside transporter-1 knockdown tunes cellular mechanics through epithelial-mesenchymal transition in pancreatic cancer cells.PharmGKB summary: gemcitabine pathwayGemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cellsGenexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinomaFinding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.Physiological and pharmacological roles of nucleoside transporter proteins.Clinical pharmacology and pharmacogenetics of gemcitabine.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.The way forward in treating pancreatic cancerPrognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes.
P2860
Q21092207-544CE18A-CB83-4318-866A-A461D6034720Q24273350-817592FA-390A-44BD-9803-D6ED91532405Q26767120-30E03160-4EB9-47DC-8967-D9C051ABC3ABQ26775135-5E1ACCAC-477A-41BA-9A02-9D1AF22D9ECBQ26801411-C6170EDE-E024-4548-959C-D029862B8D34Q26862139-E90709D9-BB66-4BFD-BC32-93797E014F93Q27004292-4343F5F0-AEAF-4BF3-8DD3-769C560F959CQ27021716-2F7C192E-1C0D-45C2-A62A-B93D6911DB22Q27684896-04AFAA9E-D358-4F5C-8C3B-86EA2A46A895Q28066268-6A44664E-3B0A-4C1C-8FE1-924A93775AF8Q28075540-F0ECD062-DD18-4DC9-922F-DF696407690BQ28087060-85F04244-04B9-4985-A78B-C40953EC27E8Q28481440-4196CF88-F04A-4416-8831-9052FBA5A134Q28486221-2167FCCC-E2E6-4E0C-A079-6A7DA14AC07FQ28550040-31E18F9C-21CD-4246-B57C-5F37A333F0A2Q30238470-65DB3B79-75A7-448C-87D3-371D575D7D63Q30244329-9BDD8AD0-ECA5-4B76-8A0D-B876A7521701Q33336057-E2D3E8CA-CBDB-4B3D-B6CF-81A046EFF5E1Q33575608-4A1D4C11-E3B8-4390-A8B7-C15D59F861D9Q33591937-EE14302A-7AC9-4E7F-9E0D-0AAE618D6842Q33711106-5A4152A1-FA8B-4668-BE28-80E08F0CFFE4Q33803923-C477586E-E615-408E-A381-9546D97540BBQ34177223-052D117E-514F-4866-A79B-7B894859A6F5Q34234101-34683D08-6A54-4203-A035-FD59CFE1BEB9Q34254837-6D281F48-0CA9-47F3-84CF-0173FE35114AQ34278045-4449309C-2468-4C63-8934-321A8369505FQ34283650-6493AD45-02E1-4B38-AF08-64779C32321CQ34337500-9D957637-AECD-4EB8-8BA3-1929FBF38297Q34435450-18D51FE4-1872-41D4-ACA1-520E402AE4D3Q34507964-17D187B5-75A0-4294-B04D-E1C252EEC1DBQ34609029-1F3F9CAD-BA20-431F-AD6B-ED37CF15858EQ34621614-182BD372-A57E-4069-A6F4-9A5CCFA34787Q34625514-05B8AD74-89A2-4B82-8684-E9CE0C9746AAQ34646772-4A2A0BC1-1EBD-4262-97C0-60392933FD68Q34792283-A2FD700C-854E-4F8D-83DA-156386350CD8Q34985979-80A61BA8-EBB9-4CF4-BC6B-9F3EAF524CD7Q35066350-532F2DAC-FED0-43CE-96CB-B2BAA5754A1EQ35076255-99F4D40A-7A1E-47A1-987F-CCA57033F958Q35086475-609B8E4B-2242-4FF6-AE79-F05B67E5F0BEQ35197256-E6FAF7B1-5A49-49B6-8E4F-29696D350CF2
P2860
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
The absence of human equilibra ...... eated pancreas adenocarcinoma.
@en
The absence of human equilibra ...... eated pancreas adenocarcinoma.
@nl
type
label
The absence of human equilibra ...... eated pancreas adenocarcinoma.
@en
The absence of human equilibra ...... eated pancreas adenocarcinoma.
@nl
prefLabel
The absence of human equilibra ...... eated pancreas adenocarcinoma.
@en
The absence of human equilibra ...... eated pancreas adenocarcinoma.
@nl
P2093
P921
P1476
The absence of human equilibra ...... reated pancreas adenocarcinoma
@en
P2093
Carol Cass
Darryl Glubrecht
James D Young
Jennifer Spratlin
Laith Dabbagh
Randeep Sangha
Raymond Lai
P304
P356
10.1158/1078-0432.CCR-04-0224
P407
P577
2004-10-01T00:00:00Z